missing translation for 'onlineSavingsMsg'
Learn More
Learn More
R&D Systems™ Recombinant Human IL-28A/IFN-lambda 2 Protein
Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility. Applications: Bioactivity
479.00 EUR
Specifications
| Gene ID (Entrez) | 282616 |
|---|---|
| Molecular Weight (g/mol) | 20.8 kDa |
| Name | IL-28A/IFN-lambda 2 |
| Quantity | 25 μg |
| Source | Mouse myeloma cell line,NS0-derived human IL-28A/IFN-lambda 2 protein, (N-terminus) Human IL-28A Val26-Val200 Accession &Num; NP_742150 DI 6-His tag (C-terminus) |
| Product Code | Brand | Formulation | Price | Quantity & Availability | |||||
|---|---|---|---|---|---|---|---|---|---|
| Product Code | Brand | Formulation | Price | Quantity & Availability | |||||
|
18196300
|
R&D Systems™
1587-IL-025/CF |
Lyophilized from a 0.2μm filtered solution in PBS. |
479.00 EUR
25µg |
Please sign in to purchase this item. Need a web account? Register with us today! | |||||
|
18156210
|
R&D Systems™
1587-IL-025 |
Lyophilized from a 0.2μm filtered solution in PBS with BSA as a carrier protein. |
479.00 EUR
25µg |
Please sign in to purchase this item. Need a web account? Register with us today! | |||||
Description
The Recombinant Human IL-28A/IFN-lambda 2 Protein is derived from NS0. The Recombinant Human IL-28A/IFN-lambda 2 Protein has been validated for the following applications: Bioactivity.Specifications
| 282616 | |
| IL-28A/IFN-lambda 2 | |
| Mouse myeloma cell line,NS0-derived human IL-28A/IFN-lambda 2 protein, (N-terminus) Human IL-28A Val26-Val200 Accession &Num; NP_742150 DI 6-His tag (C-terminus) | |
| Unconjugated | |
| 97%, by SDS-PAGE under reducing conditions and visualized by silver stain. |
| 20.8 kDa | |
| 25 μg | |
| Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70° C as supplied. 1 month, 2 to 8° C under sterile conditions after reconstitution. 3 months, -20 to -70° C under sterile conditions after reconstitution. | |
| Recombinant |
Spot an opportunity for improvement?Share a Content Correction
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title